Anti‐proliferative effects of pentagamaboronon‐0‐sorbitol on HER2‐overexpressing breast cancer cells
Indonesian Journal of Biotechnology, 2022 HER2‐positive breast cancer is an aggressive form of the disease that is associated with poor prognosis and chemo‐resistance. As such, investigation continues into the development of a new HER2‐targeted drug for breast cancer. This study investigated the
Lailatul Qodria +3 more
doaj +1 more source
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]
, 2014 The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L. +8 more
core +6 more sources
Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
Zhongliu Fangzhi Yanjiu, 2018 Objective To analyze the cardiac safety of trastuzumab on HER2 positive breast cancer patients. Methods Trastuzumab was administrated every three weeks in 185 patients with HER2 positive breast cancer.
MENG Wenjing +3 more
doaj +1 more source
Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. [PDF]
, 2016 BackgroundHER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors, primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a predictive biomarker in anti ...
Apple, Sophia K +5 more
core +2 more sources
Acta Dermato-Venereologica, 2023 is missing (Short communication)
Yui Hirano-Lotman +4 more
doaj +1 more source
Age-related Variation in Expression of Breast Cancer Tumour Markers in Iranian Patients [PDF]
Middle East Journal of Cancer, 2021 Background: There are believed to be several risk factors affecting the prognosis of breast cancer through their effect on the growth rate of tumour.
Fatemeh Homaei Shandiz +6 more
doaj +1 more source
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]
, 2015 Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F +16 more
core +2 more sources
Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab [PDF]
, 2005 Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary
Heinemann, Volker +3 more
core +1 more source
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. [PDF]
, 2012 Limited data exist regarding treatment patterns and outcomes in elderly patients with HER2-positive metastatic breast cancer (MBC). registHER is an observational study of patients (N = 1,001) with HER2-positive MBC diagnosed within 6 months of enrollment
Brufsky, Adam M +9 more
core +1 more source
Biomolecules, 2019 G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab ...
Jung Won Shin +7 more
doaj +1 more source